{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:19:59Z","timestamp":1788542399518,"version":"build-2803163510"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Interleukin inhibitors represent a standard therapeutic approach for psoriasis. However, there is still debate about the risk of new-onset inflammatory bowel disease (IBD) in psoriasis patients following interleukin inhibitor treatment. This systematic review and meta-analysis aims to evaluate the risk of new-onset IBD in psoriasis patients treated with five interleukin inhibitors (Bimekizumab, Ixekizumab, Secukinumab, Brodalumab, and Ustekinumab), providing insights to inform clinical decision-making.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>This study was registered in the PROSPERO with registration number of CRD42024608423. The databases PubMed, Embase, Cochrane Library, and Web of Science were comprehensively searched for observational studies published as full-length papers in English. The Mantel-Haenszel method with a fixed-effects model and risk difference was used to compare the risk of new-onset IBD between experimental groups (using interleukin inhibitors) and the control groups (using placebo or non-interleukin inhibitors). Sensitivity analysis was performed using the leave-one-out method for the meta-analysis. Additionally, considering the potential for underdiagnosis of IBD, a meta-analysis of the risk of diarrhea was conducted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Result<\/jats:title><jats:p>This study included 17 articles covering 21 Randomized Controlled Trials(RCTs). A total of 22 new-onset IBD cases were reported in the experimental groups, with 3, 14, 4, 1, and 0 cases in the Bimekizumab, Ixekizumab, Secukinumab, Brodalumab, and Ustekinumab group, respectively. The control group only reported 1 case of new-onset IBD. No significant difference in the risk of new-onset IBD was found between these experimental groups and control groups. Based on the fixed-effects model, the pooled risk difference for Ixekizumab group was MH RD 0.0027 (95% CI 0.0001-0.0054, I\u00b2 = 0%, P = 0.04). Sensitivity analysis indicated that the data was stable. Regarding diarrhea, a total of 95 cases were reported in the experimental groups, compared to 50 cases in the control groups. The experimental groups of Bimekizumab, Secukinumab, and Brodalumab reported 49, 45, and 1 case of diarrhea, respectively, while their control groups reported 11, 39, and 0 cases, respectively. Based on the fixed-effects model, compared to the control groups, there were no significant differences in the risk of diarrhea among psoriasis patients treated with these three interleukin inhibitors, and sensitivity analysis demonstrated good data robustness. Additionally, no cases of diarrhea were reported in the Ixekizumab group and Ustekinumab group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>There is insufficient evidence to confirm that Ustekinumab, Bimekizumab, Secukinumab, and Brodalumab significantly increase the risk of new-onset IBD. However, compared to the control group, Ixekizumab was significantly associated with an increased risk of new-onset IBD in psoriasis patients. Psoriasis patients receiving Ixekizumab treatment should remain vigilant for gastrointestinal symptoms, particularly in high-risk patients, to identify and manage potential IBD early. Additionally, compared to the control group, no significant difference was observed in the risk of diarrhea as an adverse event among patients treated with Bimekizumab, Secukinumab, and Brodalumab.<\/jats:p><\/jats:sec><jats:sec><jats:title>Systematic Review Registration<\/jats:title><jats:p><jats:uri>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD42024608423<\/jats:uri>, identifier CRD42024608423.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2025.1594998","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T05:37:54Z","timestamp":1749015474000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Risk of new-onset inflammatory bowel disease in psoriasis patients treated with five different interleukin inhibitors: a systematic review and meta-analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Jia-Xin","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long-Zhuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Kun","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"573","DOI":"10.35541\/cjd.20220839","article-title":"Guideline for the diagnosis and treatment of psoriasis in China (2023 edition)","volume":"56","year":"2023","journal-title":"Chin J Dermatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtumed.2021.02.008","article-title":"Depression and anxiety among patients with psoriasis: A correlation with quality of life and associated factors","volume":"16","author":"Bakar","year":"2021","journal-title":"J Taibah Univ Med Sci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.13621\/j.1001-5949.2023.07.0670","article-title":"Research progress on the epidemiology and risk factors of psoriasis","volume":"45","author":"Zhang","year":"2023","journal-title":"Ningxia Med J"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.35541\/cjd.20210643","article-title":"Guidelines for the treatment of psoriasis with biologic agents in China (2021)","volume":"54","year":"2021","journal-title":"Chin J Dermatol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3S","DOI":"10.1177\/1203475418811347","article-title":"Practical guidelines for managing patients with psoriasis on biologics: an update","volume":"23","author":"Poelman","year":"2019","journal-title":"J Cutaneous Med Surg"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.47102\/annals-acadmedsg.","article-title":"2023 guidelines on the management of psoriasis by the Dermatological Society of Singapore","volume":"53","author":"Oon","year":"2024","journal-title":"Ann Acad Medicine Singapore"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2010.11.055","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: Case-based presentations and evidence-based conclusions","volume":"65","author":"Menter","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/joim.v290.2","article-title":"Inflammatory bowel disease and psoriasis: modernizing the multidisciplinary approach","volume":"290","author":"Hedin","year":"2021","journal-title":"J Internal Medicine"},{"key":"B9","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/gut.52.1.65","article-title":"Increased expression of interleukin 17 in inflammatory bowel disease","volume":"52","author":"Fujino","year":"2003","journal-title":"Gut"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjy063","article-title":"Emergence of inflammatory bowel disease during treatment with secukinumab","volume":"12","author":"Fobelo Lozano","year":"2018","journal-title":"J Crohn\u2019s Colitis"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.14309\/crj.2018.56","article-title":"Rapid onset of inflammatory bowel disease after receiving secukinumab infusion","volume":"5","author":"Wang","year":"2018","journal-title":"ACG Case Rep J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41395-018-0422-z","article-title":"New onset of inflammatory bowel disease in three patients undergoing IL-17A inhibitor secukinumab: a case series","volume":"114","author":"Vernero","year":"2019","journal-title":"Off J Am Coll Gastroenterology"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2016.298","article-title":"A randomized, double-blind, placebo-controlled phase 2 study of brodalumab in patients with moderate-to-severe Crohn\u2019s disease","volume":"111","author":"Targan","year":"2016","journal-title":"Off J Am Coll Gastroenterology"},{"key":"B15","article-title":"Progress on relationship between IL-23\/IL-17 axis and inflammatory bowel disease","volume":"37","author":"Wang","year":"2021","journal-title":"Chin J Cell Mol Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07537-3","article-title":"CTLA-4-expressing ILC3s restrain interleukin-23-mediated inflammation","volume":"630","author":"Ahmed","year":"2024","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"bmj"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503824","article-title":"Phase 3 studies comparing brodalumab with ustekinumab in psoriasis","volume":"373","author":"Lebwohl","year":"2015","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1000-3614.2014.02.017","article-title":"Application of the cochrane risk of bias assessment tool in meta-analysis of randomized controlled trials","volume":"29","author":"Hongqiu","year":"2014","journal-title":"Chin Circ J"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/sim.v34.7","article-title":"Statistical methods for meta-analyses including information from studies without any events\u2014add nothing to nothing and succeed nevertheless","volume":"34","author":"Kuss","year":"2015","journal-title":"Stat medicine"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.12173\/j.issn.1004-4337.202304137","article-title":"The misuse of the I2 test in the evaluation of heterogeneity of Meta-analysis","volume":"36","author":"Wang","year":"2023","journal-title":"J Math Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.2015.172.issue-2","article-title":"Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE)","volume":"172","author":"Blauvelt","year":"2015","journal-title":"Br J Dermatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003855","article-title":"Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL","volume":"10","author":"Coates","year":"2024","journal-title":"RMD Open"},{"key":"B24","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13075-020-2099-0","article-title":"Safety results of ixekizumab with 1822.2 patient-years of exposure: an integrated analysis of 3 clinical trials in adult patients with psoriatic arthritis","volume":"22","author":"Combe","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1512711","article-title":"Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis","volume":"375","author":"Gordon","year":"2016","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00126-4","article-title":"Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial","volume":"397","author":"Gordon","year":"2021","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial","volume":"395","author":"McInnes","year":"2020","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0140-6736(22)02303-0","article-title":"Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-\u03b1 inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)","volume":"401","author":"Merola","year":"2023","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.2016.175.issue-2","article-title":"A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis","volume":"175","author":"Papp","year":"2016","journal-title":"Br J Dermatol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-036245","article-title":"Long-term effectiveness and safety of infliximab, golimumab and ustekinumab in patients with psoriatic arthritis from a Canadian prospective observational registry","volume":"10","author":"Rahman","year":"2020","journal-title":"BMJ Open"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.v182.4","article-title":"A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment","volume":"182","author":"Reich","year":"2020","journal-title":"Br J Dermatol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00125-2","article-title":"Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial","volume":"397","author":"Reich","year":"2021","journal-title":"Lancet"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224431","article-title":"Bimekizumab treatment in biologic DMARD-na\u00efve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study","volume":"82","author":"Ritchlin","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33161-7","article-title":"Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial","volume":"395","author":"Ritchlin","year":"2020","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217372","article-title":"Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis na\u00efve to biological disease-modifying antirheumatic drug: final results by week 52","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2102388","article-title":"Bimekizumab versus adalimumab in plaque psoriasis","volume":"385","author":"Warren","year":"2021","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyn204","article-title":"Commentary: Heterogeneity in meta-analysis should be expected and appropriately quantified","volume":"37","author":"Higgins","year":"2008","journal-title":"Int J Epidemiology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12874-015-0024-z","article-title":"The heterogeneity statistic I2 can be biased in small meta-analyses","volume":"15","author":"von Hippel","year":"2015","journal-title":"BMC Med Res Methodology"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1111\/apt.15397","article-title":"Systematic review with meta-analysis: risk of new onset IBD with the use of anti-interleukin-17 agents","volume":"50","author":"Yamada","year":"2019","journal-title":"Alimentary Pharmacol Ther"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.51821\/ageb","article-title":"New onset inflammatory bowel disease after initiation of anti-IL-17a treatment: a case series","volume":"87","author":"Geldof","year":"2024","journal-title":"Acta\u00a0Gastro-Enterologica Belgica"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12876-021-01936-w","article-title":"Severe drug-associated colitis with Crohn\u2019s features in setting of ixekizumab therapy for chronic plaque psoriasis","volume":"21","author":"Mu","year":"2021","journal-title":"BMC gastroenterology"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000001266","article-title":"Ustekinumab as a treatment for ixekizumab-associated new-onset crohn\u2019s disease in a patient with psoriasis","volume":"11","author":"Tan","year":"2024","journal-title":"ACG Case Rep J"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15631","article-title":"Paradoxical ulcerative colitis during adalimumab treatment of psoriasis resolved by switch to ustekinumab","volume":"178","author":"Kolios","year":"2018","journal-title":"Br J Dermatol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214273","article-title":"Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials","volume":"78","author":"Schreiber","year":"2019","journal-title":"Ann rheumatic diseases"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.13748\/j.cnki.issn1007-7693.2023.03.015","article-title":"Data mining and analysis of adverse events of interleukin-17A inhibitors in the aspects of inflammatory bowel disease based on FAERS","volume":"40","author":"Zhao","year":"2023","journal-title":"Chin J Modern Appl Pharmacy"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1674-8468.2022.04.017","article-title":"The common pathways and targeted drugs for psoriasis and inflammatory bowel disease","volume":"29","author":"Li","year":"2022","journal-title":"Diagnosis Ther J Dermato-Venereology"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-019-00340-3","article-title":"Safety of ixekizumab treatment for up to 5 years in adult patients with moderate-to-severe psoriasis: results from greater than 17,000 patient-years of exposure","volume":"10","author":"Armstrong","year":"2020","journal-title":"Dermatol Ther"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.v36.10","article-title":"Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the SERENA study","volume":"36","author":"Augustin","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1053\/j.gastro.2023.07.003","article-title":"Incidence,\u00a0prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States","volume":"165","author":"Lewis","year":"2023","journal-title":"Gastroenterology"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2025.02.026","article-title":"Advances in gut microbiota functions in inflammatory bowel disease: Dysbiosis, management, cytotoxicity assessment, and therapeutic perspectives","volume":"27","author":"Kushkevych","year":"2025","journal-title":"Comput Struct Biotechnol J"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1594998\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T05:38:03Z","timestamp":1749015483000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1594998\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":51,"alternative-id":["10.3389\/fimmu.2025.1594998"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1594998","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"article-number":"1594998"}}